Quarterly Updates19 May 2026, 09:11 pm
Anthem Bio FY26 Revenue at ₹21,243 Mn, Up 15.2% YoY
AI Summary
Anthem Biosciences Ltd announced its audited consolidated financial results for FY26 and Q4FY26. FY26 revenue from operations reached ₹21,243 Mn, with EBITDA at ₹9,896 Mn (43.4% margin) and PAT at ₹5,918 Mn (26.0% margin). Q4FY26 revenue stood at ₹6,109 Mn, with EBITDA at ₹3,184 Mn (48.1% margin) and PAT at ₹1,898 Mn (28.7% margin). The company reported a net cash position of ₹13,743 Mn as of March 31, 2026.
Key Highlights
- FY26 Consolidated Revenue from Operations: ₹21,243 Mn.
- FY26 EBITDA: ₹9,896 Mn with 43.4% margin; PAT: ₹5,918 Mn with 26.0% margin.
- Q4FY26 Consolidated Revenue from Operations: ₹6,109 Mn.
- Q4FY26 EBITDA: ₹3,184 Mn with 48.1% margin; PAT: ₹1,898 Mn with 28.7% margin.
- Net Cash position as of March 31, 2026: ₹13,743 Mn.
Price Impact
More from ANTHEM